Project: Developing a molecular predictive assay to optimise riTUXImab therapy in Rheumatoid Arthritis

We discovered that the level of type I interferon response gene expression (the so-called IFN signature) predicts rituximab (RTX) therapy response in Rheumatoid Arthritis (RA) patients. The TUXIRA consortium is designed to develop an innovative molecular diagnostic based on this patented genomic profile. The main result of TUXIRA is the PreselectSCAN: a RT-PCR test together with a dedicated IT platform for data analysis to identify RA RTX non-responders with high sensitivity and specificity.

Acronym TUXIRA (Reference Number: 10400)
Duration 01/10/2016 - 01/10/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
23906 TubaScan Limited Coordinator Netherlands
23907 Delta Diagnostics trading as Elucigene Diagnostics Partner United Kingdom
23908 Stichting VU-VUmc Partner Netherlands